ORGANOGENESIS HOLDINGS INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $2.30 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-02-26
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $1.24, a 5.08% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $1.18.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2022-03-31 was $3.38, a 65.69% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2021-03-31 was $2.04, a 22.16% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $2.30, a 125.49% increase from fiscal 2024.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $1.02.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $1.11, a 51.53% decline from fiscal 2021.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2021 was $2.29, a 19.90% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-12-31 | $2.30 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $2.29 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $1.24 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $1.24 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $1.02 10-K · filed 2025-02-27 | |||
| 2024-09-30 | $1.19 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $1.18 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $1.18 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $1.11 10-K · filed 2023-03-01 | |||
| 2022-09-30 | $1.11 10-Q · filed 2022-11-09 | |||
| 2022-06-30 | $1.11 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $3.38 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $2.29 10-K · filed 2022-03-01 | |||
| 2021-09-30 | $2.31 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | $2.15 10-Q · filed 2021-08-09 | |||
| 2021-03-31 | $2.04 10-Q · filed 2021-05-11 | |||
| 2020-12-31 | $1.91 10-K · filed 2021-03-16 | |||
| 2020-09-30 | $2.02 10-Q · filed 2020-11-09 | |||
| 2020-06-30 | $1.77 10-Q · filed 2020-08-10 | |||
| 2020-03-31 | $1.67 10-Q · filed 2020-05-11 | |||
| 2019-12-31 | $1.76 10-K · filed 2020-03-09 | |||
| 2019-09-30 | $1.77 10-Q · filed 2019-11-12 | |||
| 2019-06-30 | $1.98 10-Q · filed 2019-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |